Less than a week after they began to enroll patients in a phase three trial for a COVID-19 vaccine, Health Partners is in a holding pattern as the drugmaker leading the trial investigates a potentially unexplained illness and if it is a side effect of the shot. Last week after the trial was announced, researcher Dr. Zeke McKinney said only mild side effects were seen so far during phase one and two of the trial.

“In the phase one and two trials, really the most common side effects were pain at the site of the injection, fatigue, headache, things like that. And they were all treated well with Tylenol. So a pretty easy treatment.”

In response to an MNN inquiry, Health Partners said when the evaluation process is complete, volunteers in the study will have their appointments rescheduled. The person who became ill as a part of the trial lives in the United Kingdom. Health Partners quickly filled about one-thousand of its 15-hundred slots less than 24 hours after announcing it was participating.

McKinney also reiterated that participants in the trial would NOT be at risk of contracting COVID-19.

“In this particular case I can tell you that is not going to happen, this is actually an inactivated form of the virus. So there is no way people could get the virus from this particular vaccine.”